David Novack - Dynavax Technologies Sr. VP of Operations and Quality
DVAX Stock | USD 12.45 0.06 0.48% |
SVP
Mr. David F. Novack serves as Interim CoPresident, CoPrincipal Executive Officer of Dynavax Technologies Corporationrationration. Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr. Novack was formerly with Novartis Vaccines Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles since 2019.
Age | 63 |
Tenure | 6 years |
Professional Marks | MBA |
Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
Phone | 510 848 5100 |
Web | https://www.dynavax.com |
David Novack Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Novack against Dynavax Technologies stock is an integral part of due diligence when investing in Dynavax Technologies. David Novack insider activity provides valuable insight into whether Dynavax Technologies is net buyers or sellers over its current business cycle. Note, Dynavax Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dynavax Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Novack over six months ago Acquisition by David Novack of 20000 shares of Dynavax Technologies at 5.42 subject to Rule 16b-3 |
Dynavax Technologies Management Efficiency
Return On Tangible Assets is likely to drop to -0.0061 in 2025. Return On Capital Employed is likely to drop to -0.04 in 2025. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 166.6 M in 2025, whereas Other Assets are likely to drop slightly above 3 M in 2025. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 2 records | SVP Age | ||
Judy Joice | Durect | 68 | |
Thomas McCourt | Ironwood Pharmaceuticals | 68 |
Management Performance
Return On Equity | 0.0318 | ||||
Return On Asset | -0.0038 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Riccardo Manetti, Business President | ||
Eric Frings, Site VP | ||
Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
David Novack, Sr. VP of Operations and Quality | ||
Robert MD, Medical Development | ||
Donn Casale, Senior Officer | ||
Nicole Arndt, Sr Relations | ||
Kelly MacDonald, Senior CFO | ||
Paul Cox, VP Communications | ||
Dong Yu, Senior Research | ||
Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
John Slebir, Senior Counsel | ||
Jeff Coon, CHRO Administration | ||
Kelly CPA, Senior CFO | ||
Justin Burgess, Principal Controller | ||
Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer | ||
Meg Smith, VP Operations | ||
Todd Lopeman, Senior Operations |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0318 | ||||
Return On Asset | -0.0038 | ||||
Profit Margin | 0.08 % | ||||
Operating Margin | 0.15 % | ||||
Current Valuation | 1.13 B | ||||
Shares Outstanding | 131.46 M | ||||
Shares Owned By Insiders | 0.33 % | ||||
Shares Owned By Institutions | 99.67 % | ||||
Number Of Shares Shorted | 17.13 M | ||||
Price To Earning | 6.95 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.